


BRD4 Inhibitor-18

| | |
|---------------------------|---|
| Cat. No.: | HY-146660 |
| CAS No.: | 2451219-73-9 |
| Molecular Formula: | C ₂₆ H ₂₆ ClN ₃ O ₃ S |
| Molecular Weight: | 496.02 |
| Target: | c-Myc; Epigenetic Reader Domain; Apoptosis |
| Pathway: | Apoptosis; Epigenetics |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |



BIOLOGICAL ACTIVITY

| | | | | | | | | | | | | | | | | | |
|-------------------------------------|--|------------|----------------------------------|----------------|---------|------------------|----------|---------|---|------------|------------------------------|----------------|--------------|------------------|----------|---------|--|
| Description | BRD4 Inhibitor-18 is a highly potent BRD4 inhibitor with an IC ₅₀ value of 110 nM. BRD4 Inhibitor-18 has a hydrophobic acetylcyclopentanyl side chain. BRD4 Inhibitor-18 can significantly suppress the proliferation of MV-4-11 cells with high BRD4 level. BRD4 Inhibitor-18 has apoptosis-promoting and G ₀ /G ₁ cycle-arresting activity ^[1] . | | | | | | | | | | | | | | | | |
| IC₅₀ & Target | BRD4 110 nM (IC ₅₀) | | | | | | | | | | | | | | | | |
| In Vitro | <p>BRD4 Inhibitor-18 (compound 13f) (0-10 μM; 72 hours) can suppress the proliferation of HL-60 and MV-41 cells^[1]. BRD4 Inhibitor-18 (0.5 and 5 μM; 12 hours) significantly arrests MV-4-11 cells in G₁ phase in a dose-dependent manner^[1]. BRD4 Inhibitor-18 (0.5 and 5 μM; 12 hours) effectively induces apoptosis of MV-4-11 cells in a dose-dependent manner^[1]. BRD4 Inhibitor-18 (0.5 and 5 μM; 4 hours) inhibits the expression of c-Myc protein in a dose-dependent manner^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Proliferation Assay</p> <table border="1"> <tr> <td>Cell Line:</td> <td>HL-60 and MV-4-11^[1]</td> </tr> <tr> <td>Concentration:</td> <td>0-10 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>72 hours</td> </tr> <tr> <td>Result:</td> <td>Suppressed the proliferation of HL-60 and MV-41 cells with IC₅₀s of 5.52 μM and 0.42 μM.</td> </tr> </table> <p>Cell Cycle Analysis</p> <table border="1"> <tr> <td>Cell Line:</td> <td>MV-4-11 cells^[1]</td> </tr> <tr> <td>Concentration:</td> <td>0.5 and 5 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>12 hours</td> </tr> <tr> <td>Result:</td> <td>Significantly arrested MV-4-11 cells in G₁ phase, with the G₀/G₁ cell proportions of 50.87% and 70.66% at 0.5 and 5 μM.</td> </tr> </table> <p>Apoptosis Analysis</p> | Cell Line: | HL-60 and MV-4-11 ^[1] | Concentration: | 0-10 μM | Incubation Time: | 72 hours | Result: | Suppressed the proliferation of HL-60 and MV-41 cells with IC ₅₀ s of 5.52 μM and 0.42 μM. | Cell Line: | MV-4-11 cells ^[1] | Concentration: | 0.5 and 5 μM | Incubation Time: | 12 hours | Result: | Significantly arrested MV-4-11 cells in G ₁ phase, with the G ₀ /G ₁ cell proportions of 50.87% and 70.66% at 0.5 and 5 μM. |
| Cell Line: | HL-60 and MV-4-11 ^[1] | | | | | | | | | | | | | | | | |
| Concentration: | 0-10 μM | | | | | | | | | | | | | | | | |
| Incubation Time: | 72 hours | | | | | | | | | | | | | | | | |
| Result: | Suppressed the proliferation of HL-60 and MV-41 cells with IC ₅₀ s of 5.52 μM and 0.42 μM. | | | | | | | | | | | | | | | | |
| Cell Line: | MV-4-11 cells ^[1] | | | | | | | | | | | | | | | | |
| Concentration: | 0.5 and 5 μM | | | | | | | | | | | | | | | | |
| Incubation Time: | 12 hours | | | | | | | | | | | | | | | | |
| Result: | Significantly arrested MV-4-11 cells in G ₁ phase, with the G ₀ /G ₁ cell proportions of 50.87% and 70.66% at 0.5 and 5 μM. | | | | | | | | | | | | | | | | |

| | |
|-----------------------|--|
| Cell Line: | MV-4-11 cells ^[1] |
| Concentration: | 0.5 and 5 μ M |
| Incubation Time: | 12 hours |
| Result: | Effectively induced apoptosis of MV-4-11 cells, with apoptosis rates of 12.39% and 73.24% at at 0.5 and 5 μ M. |
| Western Blot Analysis | |
| Cell Line: | MV-4-11 cells ^[1] |
| Concentration: | 0.5 and 5 μ M |
| Incubation Time: | 4 hours |
| Result: | Inhibited the expression of c-Myc protein in a dose-dependent manner. |

REFERENCES

[1]. Li Q, Li J, Cai Y, et al. Design, synthesis and biological evaluation of novel 6-phenyl-1,3a,4,10b-tetrahydro-2H-benzo[c]thiazolo[4,5-e]azepin-2-one derivatives as potential BRD4 inhibitors. *Bioorg Med Chem.* 2020;28(15):115601.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA